Examples of compounds of the invention include the 8W variants of liraglutide and dulaglutide. The invention also relates to a method for the fully recombinant preparation of 8W GLP-1 analogues and derivatives which is more simple and thereby cheaper as compared to the preparation of known GLP-1...
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings Article Open access 05 February 2024 Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic dis...
While much work has been performed in heterologous cell systems expressing GLP1R and GIPR, we will use examples pertinent to primary tissues wherever possible to increase relevance for islet biology. 2. GLP1R expression patterns Table 1 summarizes GLP1R expression patterns and levels in the islet....
Chemical analogues of GLP-1 are currently approved for the treatment of type 2 diabetes (T2D) and obesity3,4. Moreover, peptide analogues that are unimolecular co-agonists of both GLP-1R and GCGR are currently in clinical development for the treat- ment of T2D, obesity and non-alcoholic ...
GLP-1 and analogues of GLP-1 and fragments thereof are potentially useful i.a. in the treatment of type 1 and type 2 diabetes. However, the high clearance limits the usefulness of these compounds, and thus there still is a need for improvements in this field. Accordingly, it is one ...
WO2013/164484 discloses GLP-2 analogues which comprise one or more substitutions compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. WO2016/066818 describes peptides having dual agonist activity at the GLP-1 and GLP-2 receptors, ...
GLP-1 analogues of the derivatives of the invention may be described by reference to i) the number of the amino acid residue in native GLP-1(7-37) which corresponds to the amino acid residue which is changed (i.e., the corresponding position in native GLP-1), and to ii) the actual...
GLP1 receptor agonists including fusion proteins comprising GLP1, provide an improved incretin effect and therefore, have been studied for diabetes control. Such GLP1 analogues, fusion proteins and GLP1 receptor agonists are well known in the art, with exemplary examples disclosed, for example, in...
WO2000034332A1 2000-06-15 GLP-1 ANALOGUES WO2003033671A2 2003-04-24 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS WO2004094461A2 2004-11-04 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CO...
20150374794 STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE 2015-12-31 Sensfuss et al. 20150274801 ACYLATED GLUCAGON ANALOGUES 2015-10-01 Lau et al. 20150182594 NOVEL GLUCAGON ANALOGUES 2015-07-02 Lau et al. 20130288958 Novel Glucagon Analogues 2013-10-31 Lau et al. 201...